Go to content
Galapagos NV

Galapagos NV

Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.

Publicatie datum 10 jun 2015 - 07:30
Statutaire naam Galapagos NV
Titel Galapagos DARWIN 1 and 2 studies have completed 24 weeks of treatment
Bericht Last of 886 enrolled rheumatoid arthritis (RA) patients have completed the 24 week visit Topline results from final analyses expected to be released in July and August 2015 Mechelen, Belgium; 10 June 2015 - Galapagos NV (Euronext & NASDAQ: GLPG), a clinical stage biotechnology company focused on developing novel mode of action medicines, announces that the last RA patients in its DARWIN 1 and 2 dose finding studies with filgotinib have completed their final visit. This triggers the clinical research organization's process of last 24 week data collection from both studies, to be followed by final database lock and analysis. Galapagos expects to announce topline results in late July (DARWIN 1) and in August (DARWIN 2) 2015.